143 related articles for article (PubMed ID: 9545698)
1. [Biochemical and immunological properties of the fractions of tubercle bacilli].
Azuma I
Kekkaku; 1998 Feb; 73(2):65-70. PubMed ID: 9545698
[TBL] [Abstract][Full Text] [Related]
2. [Basic studies on tuberculosis and tubercle bacilli in U.S.-Japan medical cooperative program tuberculosis panel].
Azuma I
Kekkaku; 1996 Jan; 71(1):19-23. PubMed ID: 8808264
[TBL] [Abstract][Full Text] [Related]
3. Enhancing activity of mycobacterial cell-derived adjuvants on immunogenicity of recombinant human hepatitis B virus vaccine.
Koike Y; Yoo YC; Mitobe M; Oka T; Okuma K; Tono-oka S; Azuma I
Vaccine; 1998 Dec; 16(20):1982-9. PubMed ID: 9796054
[TBL] [Abstract][Full Text] [Related]
4. Development of immunoadjuvants for immunotherapy of cancer.
Azuma I; Seya T
Int Immunopharmacol; 2001 Jul; 1(7):1249-59. PubMed ID: 11460306
[TBL] [Abstract][Full Text] [Related]
5. [Immunochemistry of tubercle bacilli, with special reference to adjuvant activity (author's transl)].
Azuma I
Kekkaku; 1981 Dec; 56(12):595-607. PubMed ID: 7035731
[No Abstract] [Full Text] [Related]
6. [Antitumor activity of bacterial fractions and related synthetic compounds].
Azuma I; Yamamura Y
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2691-9. PubMed ID: 6508322
[TBL] [Abstract][Full Text] [Related]
7. Review: inducer of cytokines in vivo: overview of field and romurtide experience.
Azuma I
Int J Immunopharmacol; 1992 Apr; 14(3):487-96. PubMed ID: 1618600
[TBL] [Abstract][Full Text] [Related]
8. Gene-inducing program of human dendritic cells in response to BCG cell-wall skeleton (CWS), which reflects adjuvancy required for tumor immunotherapy.
Ishii K; Kurita-Taniguchi M; Aoki M; Kimura T; Kashiwazaki Y; Matsumoto M; Seya T
Immunol Lett; 2005 May; 98(2):280-90. PubMed ID: 15860229
[TBL] [Abstract][Full Text] [Related]
9. Further study on relationship of anti-tuberculous protection to lung granulomata produced by intravenous injections of synthetic 6-0-mycoloyl-N-acetyl-muramyl-L-alanyl-D-isoglutamine with or without specific antigens.
Yamamoto K; Kato K; Kakinuma M; Okuyama H; Azuma I
Immunology; 1982 Jun; 46(2):473-9. PubMed ID: 7044961
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of iv mycobacterial cell wall skeleton and cell wall skeleton combined with trehalose dimycolate.
Vosika GJ; Gray GR
Cancer Treat Rep; 1983 Sep; 67(9):785-90. PubMed ID: 6883355
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of intravenous mycobacterial cell wall skeleton and trehalose dimycolate attached to oil droplets.
Vosika G; Giddings C; Gray GR
J Biol Response Mod; 1984 Dec; 3(6):620-6. PubMed ID: 6512562
[TBL] [Abstract][Full Text] [Related]
12. [Augmentation of immune defense mechanisms of the lung by romurtide].
Hasegawa J; Satoh A; Yagi K; Chida K
Nihon Kyobu Shikkan Gakkai Zasshi; 1995 Jun; 33(6):605-11. PubMed ID: 7666614
[TBL] [Abstract][Full Text] [Related]
13. [Muramyl dipeptide derivative and its clinical application].
Tsubura E
Kekkaku; 1989 Nov; 64(11):731-9. PubMed ID: 2593464
[TBL] [Abstract][Full Text] [Related]
14. Epithelioid granuloma formation by a synthetic bacterial cell wall component, muramyl dipeptide (MDP).
Tanaka A; Emori K
Am J Pathol; 1980 Mar; 98(3):733-48. PubMed ID: 6767407
[TBL] [Abstract][Full Text] [Related]
15. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
16. [Inhibition of IgE antibody formation by tubercle bacilli and muramyl peptide].
Kishimoto T
Kekkaku; 1980 Oct; 55(10):467-70. PubMed ID: 6785511
[No Abstract] [Full Text] [Related]
17. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
[TBL] [Abstract][Full Text] [Related]
18. [Synthesis and protective activity of beta-glycosides of N-acetylmuramyl-L-alanyl-D-isoglutamine with alkylalicyclic and arylaliphatic aglycons].
Zemliakov AE; Tsikalova VN; Tsikalov VV; Chirva VIa; Mulik EL; Kaliuzhin OV
Bioorg Khim; 2005; 31(6):637-44. PubMed ID: 16363137
[TBL] [Abstract][Full Text] [Related]
19. [Chemical synthesis and immunologic activities of the active unit of BCG-CWS].
Saiki I; Azuma I
Nihon Rinsho; 1981 Apr; 39(4):1861-7. PubMed ID: 7031298
[No Abstract] [Full Text] [Related]
20. Synthetic immunoadjuvants: application to non-specific host stimulation and potentiation of vaccine immunogenicity.
Azuma I
Vaccine; 1992; 10(14):1000-6. PubMed ID: 1471423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
